CRANE NXT |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 63.22 USD | +1.10% |
|
+2.66% | -34.36% |
| May. 29 | BofA Securities Adjusts Crane Price Target to $165 From $140, Maintains Buy Rating | MT |
| May. 27 | CR Double-Crane Pharmaceutical's Unit Gets Nod for Phloroglucinol Injection | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.69 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 3.68 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Industrial Machinery & Equipment
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -34.36% | 8.52B | - | ||
| +15.44% | 16.15B | C+ | ||
| -4.42% | 6.65B | A- | ||
| +43.07% | 2.08B | - | ||
| +10.43% | 1.66B | C | ||
| +10.04% | 922M | - | ||
| +17.81% | 909M | - | ||
| -6.55% | 640M | - | ||
| -16.03% | 598M | - | D | |
| -21.78% | 399M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CR Stock
- CXT Stock
- Ratings Crane NXT
